Health Catalyst 3Q 2026: Revenue $56.28M, EPS $0.53 — 10-Q Summary
Health Catalyst reported 3Q 2026 revenue of $56.28M, down 26.3% YoY, and net income of $40.5M, up 282.2% YoY. The decline was attributed to the Vitalware divestiture, migration churn, and exits from lower-margin arrangements. Earnings were boosted by a gain on the Vitalware sale.
How this was made

The 30-second read
Why it matters
The earnings release provides fresh data for traders; the mix of declining core revenue and a non‑recurring gain creates uncertainty about future earnings trajectory.
Market read
Primary earnings disclosure for a micro‑cap health‑tech company; new numbers may prompt short‑term trading activity.
What to watch
Restructuring cost reductions and potential future deals are not reflected in the current numbers.
Background
Health Catalyst filed its Q3 2026 10‑Q, highlighting a revenue decline driven by divestitures and churn, offset by a one‑time gain.
Ticker impact
Health Catalyst reported Q3 2026 revenue of $56.28M, a 26.3% YoY decline and a net income gain driven by a $65.9M pre‑tax gain on the Vitalware divestiture.
potential downside as the revenue drop outweighs the gain from the Vitalware sale
Revenue contraction signals weaker operating performance; the gain is non‑recurring, so investors may discount it.
Market effects
Health data analytics sector may see heightened scrutiny on revenue trends after this decline.
U.S. healthcare IT stocks could experience modest pressure.
Limited to investors focused on U.S. health‑tech micro‑caps.
Counterpoint
The Vitalware divestiture cash could fund strategic acquisitions, offering upside if redeployed effectively.
Key entities
- CompanyHealth Catalyst, Inc.
U.S. health‑data analytics firm (ticker HCAT).



